Track Avalo Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Avalo Therapeutics Inc. Common Stock AVTX · Stock Open Avalo Therapeutics Inc. Common Stock in new tab

7.76 USD
P/E
2.30
EPS
-2.26
P/B
0.96
ROE
-33.58
Beta
0.75
Target Price
34.80 USD
Loading chart...
Key Metrics
Earnings dateMarch 31, 2027
P/E2.30
EPS-2.26
Book Value8.10
Price to Book0.96
Debt/Equity0.04
% Insiders2.895%
Growth
Revenue Growth-0.69%
Estimates
Forward P/E-2.97
Forward EPS-2.62
Target Mean Price34.80

DCF valuation

Model fair value for Avalo Therapeutics Inc. Common Stock (AVTX)
Result
Sign in to run the valuation for AVTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Strong buy · mean target 34.80 USD (low 10.00, high 60.00) · as of 15 Nov 2026
Low 10.00
Mean 34.80
High 60.00
Price 7.76
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Avalo Therapeutics Inc. Common Stock Logo Avalo Therapeutics Inc. Common Stock Analysis (AVTX)

United States Health Care Official Website Stock

Is Avalo Therapeutics Inc. Common Stock a good investment? Avalo Therapeutics Inc. Common Stock (AVTX) is currently trading at 7.76 USD. Market analysts have a consensus price target of 34.80 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 2.30. This relatively low multiple may signal that Avalo Therapeutics Inc. Common Stock is undervalued compared to historical market norms.

Earnings Schedule: Avalo Therapeutics Inc. Common Stock is expected to release its next earnings report on March 31, 2027. The market consensus estimate for Forward EPS is -2.62.

Investor FAQ

Does Avalo Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Avalo Therapeutics Inc. Common Stock?

Avalo Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 31, 2027. The company currently has a trailing EPS of -2.26.

Company Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Exchange Ticker
NMS (United States) AVTX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 8, 2022 0.08
Dec. 29, 2023 Needs review
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion